Friends! In this video, I will analyze SOFI stock
1 extracted signal · 1 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 31 Oct 2025, 22:23 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The video discusses SoFi's stock performance, noting a 120% year-to-date increase and the presenter's initial purchase at $14, followed by dollar-cost averaging. The Q3 earnings report is highlighted as 'absolutely stunning,' with revenue growth at 38% and an adjusted EBITDA margin of 29%. The net income margin reached 15%, up from 9% in 2024. Total members increased to 12.6 million. Adjusted net revenue shows 57% YoY growth. Fee-based revenue is comprising 43% and will reach 67% and more, which is very capital light and high profitability.The company raised its guidance to $0.37 per share, up from $0.31 in the last quarter. Two near-term catalysts were identified: re-entering crypto and a potential S&P 500 inclusion. A valuation model sets a price target of $68.73 based on best-case growth scenarios out to 2030 and an exit PE ratio of 40, reflecting a 17.3% annual return, while still maintaining the investment due to the long-term growth potential. The presenter trims the position given the price point given short term considerations, with an exit at $31.50 due to a belief it might be fully valued in the short term.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
